THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO PROVIDE A NOVEL HEPARIN-LIKE MOLECULAR COMPONENT FOR SMALL BLOOD VESSEL PROSTHESES THAT WILL SIMULTANEOUSLY REDUCE OR PREVENT PERI- ANASTOMOTIC HYPERPLASIA AND REDUCE THROMBOGENICITY.

THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO PROVIDE A NOVEL HEPARIN-LIKE MOLECULAR COMPONENT FOR SMALL BLOOD VESSEL PROSTHESES THAT WILL SIMULTANEOUSLY REDUCE OR PREVENT PERI- ANASTOMOTIC HYPERPLASIA AND REDUCE THROMBOGENICITY. THE IMMEDIATE SPECIFIC AIM IS TO OBTAIN A NEW SUPPLY OF THIS MATERIAL FROM ITS INVERTEBRATE SOURCE AND TO TEST ITS ANTIPROLIFERATIVE AND ANTICOAGULANT ACTIVITY. THE FIRST PHASE OF THE PROJECT WILL INVOLVE EXTRACTION AND ASSAY FOR ANTIPROLIFERATIVE ACTIVITIES ON AORTIC SMOOTH MUSCLE CELLS. SUBSEQUENT RESEARCH WILL INVOLVE TESTS ON HUMAN ENDOTHELIAL CELLS, BONDING TO THE STRUCTURAL POLYMER, AND LATER, IN COLLABORATION WITH CARDIOVASCULAR SURGEONS, TESTS FOR DEVELOPMENT OF THE PRODUCT FOR CLINICAL USE. THE COMMERCIALVALUE OF THE PRODUCT ARISES FROM THE EXPANDING MARKET FOR CARDIOVASCULAR PROSTHESES IN GENERAL AND FOR IMPROVED SMALL BLOOD VESSEL PROSTHESES IN PARTICULAR.